The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease

Jose L. Barboza, Michael S. Okun, Baharak Moshiree

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Introduction: Parkinsons disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD.Areas covered: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews.Expert opinion: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patients motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.

Original languageEnglish (US)
Pages (from-to)2449-2464
Number of pages16
JournalExpert Opinion on Pharmacotherapy
Volume16
Issue number16
DOIs
StatePublished - Nov 2 2015

Fingerprint

Blind Loop Syndrome
Gastroparesis
Constipation
Parkinson Disease
Laxatives
Therapeutics
Gastrointestinal Tract
Serotonin 5-HT4 Receptor Agonists
Receptors, Serotonin, 5-HT4
Motilin
Muscarinic Agonists
Preexisting Condition Coverage
Ghrelin
Dopamine Antagonists
Probiotics
Expert Testimony
Anti-Bacterial Agents
Morbidity

Keywords

  • 5-HT receptor agonists
  • autonomic nervous system dysfunction
  • azithromycin
  • constipation
  • domperidone
  • dysmotility
  • erythromycin
  • gastrointestinal
  • gastroparesis
  • iberogast
  • linaclotide
  • lubiprostone
  • mosapride
  • nizatidine
  • non-motor symptoms
  • Parkinson's disease
  • PEG
  • probiotics
  • prucalopride
  • rifaximin
  • RM-131
  • small intestinal bacterial overgrowth syndrome
  • STW5
  • TZP-101
  • TZP-102
  • ulimorelin

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease. / Barboza, Jose L.; Okun, Michael S.; Moshiree, Baharak.

In: Expert Opinion on Pharmacotherapy, Vol. 16, No. 16, 02.11.2015, p. 2449-2464.

Research output: Contribution to journalArticle

@article{dd15f68548284bb7827ca70d844bee77,
title = "The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease",
abstract = "Introduction: Parkinsons disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD.Areas covered: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews.Expert opinion: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patients motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.",
keywords = "5-HT receptor agonists, autonomic nervous system dysfunction, azithromycin, constipation, domperidone, dysmotility, erythromycin, gastrointestinal, gastroparesis, iberogast, linaclotide, lubiprostone, mosapride, nizatidine, non-motor symptoms, Parkinson's disease, PEG, probiotics, prucalopride, rifaximin, RM-131, small intestinal bacterial overgrowth syndrome, STW5, TZP-101, TZP-102, ulimorelin",
author = "Barboza, {Jose L.} and Okun, {Michael S.} and Baharak Moshiree",
year = "2015",
month = "11",
day = "2",
doi = "10.1517/14656566.2015.1086747",
language = "English (US)",
volume = "16",
pages = "2449--2464",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "16",

}

TY - JOUR

T1 - The treatment of gastroparesis, constipation and small intestinal bacterial overgrowth syndrome in patients with Parkinsons disease

AU - Barboza, Jose L.

AU - Okun, Michael S.

AU - Moshiree, Baharak

PY - 2015/11/2

Y1 - 2015/11/2

N2 - Introduction: Parkinsons disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD.Areas covered: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews.Expert opinion: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patients motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.

AB - Introduction: Parkinsons disease (PD) affects the nerves of the entire gastrointestinal (GI) tract and may result in profound gastrointestinal (GI) dysfunction leading to poor patient outcomes. Common GI disturbances in patients with PD include gastroparesis (GP), constipation and small intestinal bacterial overgrowth syndrome (SIBO). In particular, GP is difficult to treat due to the limited options available and precautions, contraindications and adverse effects associated with the approved treatments. Moreover, some commonly used medications can worsen pre-existing PD.Areas covered: Our review will focus on treatment options for GP and SIBO with motilin agonists, dopamine receptor antagonists, Ghrelin agonists muscarinic agonists, 5-HT4 receptor agonists, antibiotics, probiotics and herbal formulation such as iberogast. Constipation occurs in the majority of patients with PD and fortunately many treatments are now available. Our review is based on original papers or reviews selected from PUBMED search and Cochrane reviews.Expert opinion: Motility disorders of the GI tract are found frequently in patients with PD and treating the underlying GI disorders caused by PD with various prokinetics and laxatives is paramount in achieving improvements in patients motor function. Various prokinetics and laxatives are now available to provide some relief of the GI morbidity caused by PD leading even to better absorption of even the PD treatments.

KW - 5-HT receptor agonists

KW - autonomic nervous system dysfunction

KW - azithromycin

KW - constipation

KW - domperidone

KW - dysmotility

KW - erythromycin

KW - gastrointestinal

KW - gastroparesis

KW - iberogast

KW - linaclotide

KW - lubiprostone

KW - mosapride

KW - nizatidine

KW - non-motor symptoms

KW - Parkinson's disease

KW - PEG

KW - probiotics

KW - prucalopride

KW - rifaximin

KW - RM-131

KW - small intestinal bacterial overgrowth syndrome

KW - STW5

KW - TZP-101

KW - TZP-102

KW - ulimorelin

UR - http://www.scopus.com/inward/record.url?scp=84947491451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84947491451&partnerID=8YFLogxK

U2 - 10.1517/14656566.2015.1086747

DO - 10.1517/14656566.2015.1086747

M3 - Article

C2 - 26374094

AN - SCOPUS:84947491451

VL - 16

SP - 2449

EP - 2464

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 16

ER -